 DELRAY BEACH, Fla., Jan. 12, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, and First Wave Bio, Inc., First Wave Bio a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions, today jointly announced the United States Patent and Trademark Office USPTO has provided a notice of allowance for issuance of a patent U.S. patent application number 16835,307 that covers use of niclosamide as a treatment for COVID-19-associated GI disease. 